Compare LAFAU & GRMLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAFAU | GRMLW |
|---|---|---|
| Founded | N/A | N/A |
| Country | France | United States |
| Employees | N/A | 5 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2025 | 2022 |
| Metric | LAFAU | GRMLW |
|---|---|---|
| Price | $10.13 | $0.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.6K | ★ 28.3K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.98 | $0.10 |
| 52 Week High | $11.29 | $0.38 |
| Indicator | LAFAU | GRMLW |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 46.06 |
| Support Level | $10.00 | N/A |
| Resistance Level | $10.15 | $0.38 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 5.69 | 17.47 |
Lafayette Acquisition Corp is a blank check company engaged in effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.